Combination Shows Promise in Metastatic ESR1-Mutant Breast Cancer

(MedPage Today) -- A novel drug combination led to clinically meaningful antitumor activity in metastatic ESR1-mutated, estrogen receptor-positive (ER+)/HER2-negative breast cancer that had progressed on CDK4/6 inhibition, a small prospective study...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news